Venue | Press Room | Subscribe | Site Map
TechConnect Summit 2006
Home | About the Summit | Program | Advisory Boards | About TechConnect

Producing Sponsor


Platinum Sponsor

Welsh & Katz, Ltd.

Gold Sponsor

ISTC International Science & Technology Center

Ventures Enabling Sponsor

Atomic Venture Partners

Press Sponsor

Business Wire

Partnering Sponsor


Supporting Organizations

Boston University
Midwest Research University Network

Media Sponsors

(joint with Nanotech 2006) Nature
R&D Magazine

Summit News

Event Contact

Jennifer Rocha
955 Massachusetts Ave. #313
Cambridge, MA 02139
Phone: (774) 249-8514

Emergence of a R-Type Ca2+ Channel Contributes to Cerebral Artery Constiction Following Subarachnoid Hemmorage

Organization:University of Vermont, MA, US
I.P. Brief:Cerebral aneurysm rupture and subarachnoid hemorrage (SAH) inflict disability and death among thousands of individuals each year. The consequences of SAH following cerebral aneurysm rupture are devastating with mortality rates as high as 50% and the majority of survivors left with moderate to severe disability.
Summary of I.P.:Cerebral vasospasm, characterized as a delayed and sustained arterial constriction, is a major contributor to high morbidity and mortality rates. Large diameter arteries have been implicated in contributing to decreased blood flow resulting in SAH. The invention is based in part on the discovery that small diameter arteries have R-type voltage dependent calcium channels that are involved in regulating calcium flow and play an important role in decreased cerebral blood flow observed following SAH. It has been discovered that SAH leads to enhanced Ca2+ entry in myocytes of small diameter cerebral arteries through the emergence of R-type voltage-dependent Ca2+ channels (VDCCs) encoded by the gene Cav2.3. We believe that the administration of an R-type voltage-dependent calcium channel inhibitor will allow the management of the cerebral blood flow during a time when it would normally decrease blood flow in small diameter arteries. The emergence of Cav2.3 in cerebral arteries following subarachnoid hemorrhage is unique and the first to be described in the expression of this ion channel in vascular smooth muscle. A unique peptide has been identified that may reverse subarachnoid hemorrhage-induced vasospasm.
Patent:Provisional Patent filed
Keywords:Aneurysm, Cerebral vasospasm, Calcium Channel
Primary Industry:Pharma & Biotech
Specific Market:Cerebral aneurysm rupture and subarachnoid hemorrage (SAH)
Market Size:Unknown for the specific market size
State of the Art:There is no current, effective treatment
Figures of Merit:This technology will provide a much more effective management of cerebral blood flow reducing the damage from arterial constriction.
Tech.  Obstacles:Commercial partner needed to move from current animal work to human clinicals.
Market Obstacles:Need to identify with a commercial partner.
Publications:None available at this time.
Research Team:George Wellman, Masanori Ishiguro


Home | About the Summit | Program | Advisory Boards | About TechConnect
Terms of use | Privacy policy | Contact | TechConnect Home
© 2005 TechConnect. All rights reserved.